Amarin Corporation plc (AMRN)
AMRN Stock Price Chart
Explore Amarin Corporation plc interactive price chart. Choose custom timeframes to analyze AMRN price movements and trends.
AMRN Company Profile
Discover essential business fundamentals and corporate details for Amarin Corporation plc (AMRN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Apr 1993
Employees
275.00
Website
https://www.amarincorp.comCEO
Aaron D. Berg
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
AMRN Financial Timeline
Browse a chronological timeline of Amarin Corporation plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.56.
Earnings released on 30 Jul 2025
EPS came in at -$0.03 surpassing the estimated -$0.66 by +95.45%, while revenue for the quarter reached $46.62M , beating expectations by +10.89%.
Earnings released on 7 May 2025
EPS came in at -$0.04 surpassing the estimated -$1.12 by +96.43%, while revenue for the quarter reached $42.02M , missing expectations by -7.16%.
Stock split effective on 11 Apr 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Mar 2025
EPS came in at -$2.40 falling short of the estimated -$1.20 by -100.00%, while revenue for the quarter reached $62.31M , beating expectations by +22.78%.
Earnings released on 30 Oct 2024
EPS came in at -$1.00 matching the estimated -$1.00, while revenue for the quarter reached $42.30M , beating expectations by +33.46%.
Earnings released on 31 Jul 2024
EPS came in at $0.20 surpassing the estimated $0.10 by +100.00%, while revenue for the quarter reached $67.57M , beating expectations by +66.38%.
Earnings released on 1 May 2024
EPS came in at -$0.20 surpassing the estimated -$0.80 by +75.00%, while revenue for the quarter reached $56.49M , beating expectations by +10.71%.
Earnings released on 29 Feb 2024
EPS came in at -$0.01 falling short of the estimated -$0.01 by -66.67%, while revenue for the quarter reached $75.36M , beating expectations by +18.11%.
Earnings released on 1 Nov 2023
EPS came in at -$0.05 falling short of the estimated -$0.05 by -11.11%, while revenue for the quarter reached $66.06M , beating expectations by +12.63%.
Earnings released on 2 Aug 2023
EPS came in at $0.40 surpassing the estimated -$0.40 by +200.00%, while revenue for the quarter reached $80.17M , beating expectations by +7.58%.
Earnings released on 3 May 2023
EPS came in at $0.40 surpassing the estimated -$0.20 by +300.00%, while revenue for the quarter reached $85.98M , beating expectations by +6.99%.
Earnings released on 1 Mar 2023
EPS came in at $0.40 surpassing the estimated $0.20 by +100.00%, while revenue for the quarter reached $90.25M , beating expectations by +9.80%.
Earnings released on 27 Oct 2022
EPS came in at $0.40 surpassing the estimated -$0.40 by +200.00%, while revenue for the quarter reached $89.88M , beating expectations by +1.94%.
Earnings released on 3 Aug 2022
EPS came in at -$3.60 falling short of the estimated -$1.40 by -157.14%, while revenue for the quarter reached $94.44M , beating expectations by +7.00%.
Earnings released on 4 May 2022
EPS came in at -$1.20 falling short of the estimated -$0.40 by -200.00%, while revenue for the quarter reached $94.63M , missing expectations by -26.24%.
Earnings released on 1 Mar 2022
EPS came in at $1.20 surpassing the estimated $0.60 by +100.00%, while revenue for the quarter reached $144.49M , beating expectations by +2.23%.
Earnings released on 3 Nov 2021
EPS came in at $0.60 surpassing the estimated -$0.20 by +400.00%, while revenue for the quarter reached $142.04M , missing expectations by -12.73%.
Earnings released on 5 Aug 2021
EPS came in at $0.60 surpassing the estimated -$1.00 by +160.00%, while revenue for the quarter reached $154.49M , beating expectations by +1.18%.
Earnings released on 29 Apr 2021
EPS came in at $0.60 surpassing the estimated -$0.05 by +1.30K%, while revenue for the quarter reached $142.17M , missing expectations by -42.06%.
Earnings released on 25 Feb 2021
EPS came in at $0.80 surpassing the estimated $0.28 by +190.07%, while revenue for the quarter reached $167.25M , missing expectations by -62.96%.
Earnings released on 5 Nov 2020
EPS came in at $0.20 falling short of the estimated $0.60 by -66.67%, while revenue for the quarter reached $156.50M , beating expectations by +100.00%.
AMRN Stock Performance
Access detailed AMRN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.